Testicular cancer · 7 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Sunitinib monotherapy Variant #01 | — | R 33 433 | 42d | ~8.4 mo | ~34.0 mo | ~2 | ~R 49 300 PFS proxy · indirect | 29 |
Oxaliplatin and Bevacizumab Variant #01 | — | R 20 347 | 14d | — | — | ~14 | ~R 284 860 indirect | — |
Gemcitabine, Oxaliplatin, Paclitaxel Variant #01 | — | R 6 149 | 21d | — | — | ~2 | ~R 12 299 indirect | — |
Gemcitabine and Paclitaxel Variant #01 | — | R 5 224 | 21d | — | ~7.8 mo | ~6 | ~R 31 344 PFS proxy · indirect | — |
GemOx Variant #01 | — | R 2 937 | 14d | ~5.0 mo | ~9.0 mo | ~7 | ~R 20 560 PFS proxy · indirect | 5 |
Etoposide monotherapy Variant #01 | — | R 1 231 | 28d | — | — | ~6 | ~R 7 386 indirect | — |
Plicamycin monotherapy Variant #01 Partial | — | — | 30d | — | — | ~2 | — | — |
7 of 7 regimens shown